An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection.
Regul Toxicol Pharmacol. 2017 Nov;90:144-152. doi: 10.1016/j.yrtph.2017.09.001. Epub 2017 Sep 5.
Regul Toxicol Pharmacol. 2017.
PMID: 28887049
Review.